ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer CEO picks new team

August 21, 2006 | APPEARED IN VOLUME 84, ISSUE 34

Jeffrey B. Kindler, Pfizer's newly appointed CEO, has unveiled a new management organization. Kindler has named David L. Shedlarz, a vice chairman who had been one of the front-runners for the CEO position, as his principal deputy. Among Shedlarz' expanded responsibilities are Pfizer's global manufacturing operations, strategic planning, licensing, business development, and technology. The new team does not include Karen Katen, vice chairman and head of Pfizer's human health division and another CEO contender. She has decided to leave the firm. Kindler also has established a new executive leadership team that includes Pfizer Global R&D President John LaMattina, Worldwide Pharmaceutical Operations President Ian Read, and Chief Medical Officer Joe Feczko.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment